Table 3.
Univariate and multivariate analyses of factors associated with OS of patients with ENKTL treated with curative intent
| Variable | Univariate |
Multivariate |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age > 60 y | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 0.45 | 0.18-1.16 | .099 | 0.46 | 0.16-1.32 | .149 |
| B symptoms | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.20 | 0.43-3.3 | .729 | — | — | — |
| Stage | ||||||
| I | 1 | — | — | 1 | — | — |
| II, III, or IV | 2.92 | 1.09-7.81 | .033 | 1.77 | 0.55-5.73 | .337 |
| Serum LDH > ULN | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 2.09 | 0.67-6.53 | .204 | — | — | — |
| Regional LN involvement | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.33 | 0.5-3.59 | .567 | — | — | — |
| Nasal lesion | ||||||
| Present | 1 | — | — | — | — | — |
| Absent | 0.46 | 0.18-1.20 | .112 | — | — | — |
| Distant LN involvement | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.51 | 0.34-6.65 | .584 | — | — | — |
| STAT3 mutation | ||||||
| Negative | 1 | — | — | — | — | — |
| Positive | 0.75 | 0.24-2.33 | .617 | — | — | — |
| BCOR mutation | ||||||
| Negative | 1 | — | — | 1 | — | — |
| Positive | 9.71 | 2.57-36.72 | <.001 | 6.41 | 1.33-30.86 | .021 |
| TP53 mutation | ||||||
| Negative | 1 | — | — | — | — | — |
| Positive | 2.69 | 0.75-9.62 | .128 | — | — | — |
| pSTAT3 ≥ 30% | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 2.05 | 0.67-6.26 | .206 | — | — | — |
| CD30 ≥ 30% | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.64 | 0.65-4.16 | .299 | — | — | — |
| MYC ≥ 40% | ||||||
| No | 1 | — | — | — | — | — |
| Yes | 1.96 | 0.73-5.26 | .179 | — | — | — |
BSC, best supportive care; CTX, chemotherapy; LN, lymph node; RT, radiotherapy; UNL, upper normal limit.